恒瑞医药(600276.SH)：HRS-4642注射液等多款药物获得临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries have received approval for clinical trials of HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Adebali monoclonal antibody injection, Bevacizumab injection, SHR-A2102 for injection, Apalutamide capsules, and Darsylis sulfate tablets [1] - A specific trial for HRS-4642 will focus on its safety, tolerability, and efficacy in combination with anti-tumor drugs in solid tumor subjects, categorized as a Phase I/II study [1]